source
- Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapiesMark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments. The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" the…
- Isomorphic Labs' soaring valuation sparks debate over AI’s impact on drug development and healthcare costsIsomorphic Labs, a biotech spin‑out that applies generative AI to design new medicines, recently secured a multi‑billion‑dollar valuation that has captured industry attention. The lofty figure is…